Clinicopathological Features of Remnant Gastric Cancer After Gastrectomy

Background Remnant gastric cancer (RGC) encompasses all cancers arising from the remnant stomach. Various studies have reported on RGC and its prognosis, but no consensus on its surgical treatment and postoperative management has been reached. Moreover, the correlation between the clinicopathological characteristics and long-term outcomes of RGC remains unclear. This study investigated the clinicopathological factors associated with the long-term survival of RGC patients. Methods The medical records (March 1993-September 2020) of 104 RGC patients from Tokyo Medical University Hospital database were analyzed. Of these 104 patients, the medical records of 63 patients who underwent surgical curative resection were analyzed using R. Kaplan-Meier plots of cumulative incidence of RGC were made. Differences in survival rates were compared using the log-rank test. Prognostic factors were analyzed using multivariate Cox regression analysis ( P < .05). Results Of the 104 RGC patients, 63 underwent total remnant stomach excision. The median time from the first surgery to the total excision was 10 years. The 5-year survival rate of the 63 RGC patients was .55 ((95% CI); .417-.671). The clinicopathological factors that were significantly associated with the long-term outcome of the RGC patients were tumor diameter (≥3.5 cm), presence or absence of combined resection of multiple organs, tumor invasion (deeper than T2), TNM stage, and postoperative morbidity. The multivariate Cox regression analysis showed that tumor invasion depth was the only independent prognostic factor for RGC patients [HR (95% CI): 5.49 (2.629-11.5), P ≤ .005]. Conclusions Among prognostic factors, tumor invasion depth was the only independent factor affecting RGC’s long-term outcome.

Characteristics And Prognostic Value of Lymph Node Metastasis Along Recurrent Laryngeal Nerves in Thoracic Esophageal Squamous Cell Carcinoma

Background: Though the value of lymph node (LN) dissection along bilateral recurrent laryngeal nerve (RLN) has been debated and emphasized in recent years in thoracic esophageal squamous cell carcinoma (ESCC). However, the characteristics of nodal metastasis along RLN chain has not been clarified. This study aimed to investigate the characteristics of nodal metastasis along recurrent laryngeal nerves and the influence of these metastasis on the prognosis of thoracic ESCC.Patients and Methods: 339 eligible patients with thoracic ESCC who underwent esophagectomy with a three-field(3-FL) or two-field(2-FL) lymph node dissection from March 2015 to December 2018 were included in this study, consisting of 282 males and 57 females with a mean age of 60.6 years (range,40-80 years). The association of LN metastasis near RLN with clinicopathologic factors and its influence on survival were analyzed. Results: Among the 339 patients, 96 (28.3%) had LN metastasis along bilateral recurrent laryngeal nerves, 76 (22.4%) with positive LNs along right RLN and 47 (13.9%) along the left RLN. There was a significant difference in the metastasis rate between the LNs along right RLN and along the left RLN (P=0.004). The LN metastasis rate along RLN was significantly correlated with primary tumor locations (upper vs middle vs lower: 35.1% vs 30.9% vs 15.6%; P=0.015), tumor invasion depth (T3/T4 vs T1 vs T2: 36.2% vs 15.8% vs 26.2%, P=0.001 ) and degree of differentiation (well vs moderately vs poorly: 9.3% vs 29.3% vs 33.9%; P=0.009), subcarinal and left tracheobronchial lymph node metastasis (positive vs negative:58.1% vs 25.3%, P＜0.001), abdominal LN metastasis (positive vs negative:41.2% vs 24.0%, P=0.003 ), but was not significantly correlated with age, gender and tumor length. The median follow-up time for this study was 34 months. The cumulative 1-, 2- and 3-year overall survival rates were 95.7%, 86.6% and 82.2% in RLN-LN(-) group versus 81.5%, 67.4% and 53.7% in the RLN-LN(+) group, with a significant difference between two group (HR=2.975,95% CI:1.918-4.614, P＜0.01). Conclusions: The lymph node metastasis along RLNs was significantly correlated with primary tumor locations, tumor invasion depth, tumor differentiation, metastasis in the LNs of other stations, and indicate poor prognosis in ESCC.

The Effect of Immune-Related Genes on Colonic Adenocarcinoma Prognosis

Colorectal adenocarcinoma (COAD) is the most common type of colon cancer, and its occurrence is intimately associated with immune-related gene (IRG) expression. In this research, the IRG expression was analyzed and 484 were found significantly different between COAD and normal tissue. To construct a COAD patient IRGs-prognosis model, 11 of the IRGs were selected by multivariate Cox analysis. IRGs in the model were closely related to tumor invasion depth, lymphoid involvement, distant metastasis, stage, and age. This work lays the foundation for future scientific research and clinical work related to COAD.

Expression Level and Clinical Significance of NKILA in Human Cancers: A Systematic Review and Meta-Analysis

Background. A number of researches focused on the study of tumors have concluded that the expression level of lncRNA NKILA was decreased in different tumors. This is an indication that NKILA might influence the start and growth of a cancer. In addition, studies have fatalities and worsening health of cancer patients is associated with a reduced level of NKILA. Results. The results are the collective screening of nine total studies which included 937 cancer patients. The prognosis of the meta-analysis indicated that cancer patients with a higher expression of NKILA had an overall longer survival (OS) (HR=0.808, 95% CI: 0.736, 0.887); with regard to the clinical prognosis, the results indicated that reduced NKILA was associated with advanced clinical stage (OR=0.313, 95% CI: 0.225, 0.434), poor histological grades (OR=0.833, 95% CI: 0.508, 1.367), positive lymph node metastasis (OR=0.253, 95% CI: 0.144, 0.444), and additional tumor invasion depth (OR=0.326, 95% CI: 0.234, 0.454). Materials and Methods. Related research conducted was accessed by searching in PubMed and Web of Science with the keywords. The accessed material was till the 25th of February, 2020. The present quantitative meta-analysis was done using Stata SE12.0. The aim of the meta-analysis was to investigate the relationship between NKILA expression level and clinical prognosis. Conclusions. In the result of this meta-analysis, decreased NKILA expression is typical of different kinds of cancer. Moreover, it can perform as a predictive element of prognosis in varied kinds of cancer. Nonetheless, till now, it is deemed essential to carry out larger-size as well as better designed research works for the confirmation of our findings.

Clinicopathologic Significance of TROP2 and Phospho-TROP2 in Gastric Cancer

Background: Trophoblast cell-surface antigen 2 (TROP2) is a transmembrane glycoprotein expressed in epithelial cells. TROP2 overexpression has been reported to be correlated with malignant progression in most carcinomas, but TROP2 showed a tumor-suppressive function in some types of cancers. We currently developed a novel antibody against phospho-TROP2 (pTROP2). Since the function of TROP2 is controversial, we then aimed to clarify the clinicopathologic significance of TROP2 and pTROP2 expression in human gastric cancer (GC) in this study.Methods: We retrospectively analyzed the cases of 704 GC patients who underwent gastrectomy. The expressions of TROP2 and pTROP2 in each tumor were evaluated by immunohistochemistry. We analyzed the correlation between the GC patients' clinicopathologic features and the TROP2 and pTROP2 expression in their tumors.Results: Overexpression of TROP2 and that of pTROP2 were identified in 330 (46.9%) and 306 (43.5%) of the 704 GC patients, respectively. TROP2 overexpression was significantly correlated with the histological intestinal type, high tumor invasion depth (T3/T4), lymph node metastasis, lymphatic invasion, and venous invasion. In contrast, pTROP2 overexpression was significantly correlated with intestinal type, low tumor invasion depth (T1/2), no lymph node metastasis, and no lymphatic invasion. TROP2 overexpression was significantly associated with poorer overall survival (p<0.01, log rank), whereas pTROP2 overexpression was significantly associated with better overall survival (p<0.01, log rank).Conclusion: TROP2, but not pTROP2, might be associated with the metastatic ability of GC, resulting in poor prognoses for GC patients.

Clinicopathological and Prognostic Value of SNHG6 in Cancers: a Systematic Review and a Meta-analysis

Background The long non-coding RNA small nucleolar RNA host gene 16 (lncRNA SNHG6) is dysregulated in various malignant tumor. However, a definite conclusion on the clinical value of lncRNA SNHG6 expression in human cancers has not been determined. The purpose of the present meta-analysis was to comprehensively elucidate the association between SNHG6 expression and clinical outcomes in cancers. Methods A systematic search was performed through the PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wangfang databases for relevant studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were collected to estimate the prognostic value, and the odds ratios (ORs) with 95% CIs were used to evaluate the relationship between lncRNA SNHG6 expression and clinicopathological features, including tumor invasion depth, lymph node metastasis (LNM), distance metastasis (DM), and TNM stage. Results A total of 914 patients from 13 studies were included in this meta-analysis. The pooled results suggested that evaluated SNHG6 expression could predict an unfavorable overall survival (OS) (HR = 2.04, 95% CI:1.56~2.52) with no heterogeneity ( I 2 = 0.0%, p = 0.996). Subgroup analysis indicated a significant association between high SNHG6 expression and shorter OS in studies with digestive system cancers (HR = 2.05, 95%CI: 1.47-2.62), sample size < 70 (HR = 2.70, 95%CI: 1.29-4.11), and univariate and multivariate analysis (HR = 2.04, 95%CI: 1.44-2.64). Moreover, high SNHG6 expression was positively correlated with tumor invasion depth (OR = 1.76, 95%CI: 1.18-2.63), LNM (OR = 1.60, 95%CI: 1.18-2.17), DM (OR = 1.90, 95%CI: 1.37-2.64) and advanced TNM stage (OR = 1.88, 95%CI: 1.36-2.60) in patients with cancers. Conclusions High lncRNA SNHG6 expression was correlated with tumor invasion depth, LNM, DM, and advanced TNM stage, suggesting that SNHG6 may serve as a promising prognostic biomarker of human cancers.

Clinicopathological and Prognostic Value of SNHG6 in Cancers: a Systematic Review and a Meta-analysis

Background The long non-coding RNA small nucleolar RNA host gene 16 (lncRNA SNHG6) is dysregulated in various malignant tumor. However, a definite conclusion on the clinical value of lncRNA SNHG6 expression in human cancers has not been determined. The purpose of the present meta-analysis was to comprehensively elucidate the association between SNHG6 expression and clinical outcomes in cancers. Methods A systematic search was performed through the PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wangfang databases for relevant studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were collected to estimate the prognostic value, and the odds ratios (ORs) with 95% CIs were used to evaluate the relationship between lncRNA SNHG6 expression and clinicopathological features, including tumor invasion depth, lymph node metastasis (LNM), distance metastasis (DM), and TNM stage. Results A total of 914 patients from 13 studies were included in this meta-analysis. The pooled results suggested that evaluated SNHG6 expression could predict an unfavorable overall survival (OS) (HR = 2.04, 95% CI:1.56~2.52) with no heterogeneity ( I 2 = 0.0%, p = 0.996). Subgroup analysis indicated a significant association between high SNHG6 expression and shorter OS in studies with digestive system cancers (HR = 2.05, 95%CI: 1.47-2.62), sample size < 70 (HR = 2.70, 95%CI: 1.29-4.11), and univariate and multivariate analysis (HR = 2.04, 95%CI: 1.44-2.64). Moreover, high SNHG6 expression was positively correlated with tumor invasion depth (OR = 1.76, 95%CI: 1.18-2.63), LNM (OR = 1.60, 95%CI: 1.18-2.17), DM (OR = 1.90, 95%CI: 1.37-2.64) and advanced TNM stage (OR = 1.88, 95%CI: 1.36-2.60) in patients with cancers. Conclusions High lncRNA SNHG6 expression was correlated with tumor invasion depth, LNM, DM, and advanced TNM stage, suggesting that SNHG6 may serve as a promising prognostic biomarker of human cancers.

Clinicopathological and Prognostic Value of SNHG6 in Cancers: a Systematic Review and a Meta-analysis

Background: The long non-coding RNA small nucleolar RNA host gene 16 (lncRNA SNHG6) is dysregulated in various malignant tumor. However, a definite conclusion on the clinical value of lncRNA SNHG6 expression in human cancers has not been determined. The purpose of the present meta-analysis was to comprehensively elucidate the association between SNHG6 expression and clinical outcomes in cancers.Methods: A systematic search was performed through the PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wangfang databases for relevant studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were collected to estimate the prognostic value, and the odds ratios (ORs) with 95% CIs were used to evaluate the relationship between lncRNA SNHG6 expression and clinicopathological features, including tumor invasion depth, lymph node metastasis (LNM), distance metastasis (DM), and TNM stage. Results: A total of 914 patients from 13 studies were included in this meta-analysis. The pooled results suggested that evaluated SNHG6 expression could predict an unfavorable overall survival (OS) (HR = 2.04, 95% CI:1.56~2.52) with no heterogeneity (I2 = 0.0%, p = 0.996). Subgroup analysis indicated a significant association between high SNHG6 expression and shorter OS in studies with digestive system cancers (HR = 2.05, 95%CI: 1.47-2.62), sample size < 70 (HR = 2.70, 95%CI: 1.29-4.11), and univariate and multivariate analysis (HR = 2.04, 95%CI: 1.44-2.64). Moreover, high SNHG6 expression was positively correlated with tumor invasion depth (OR = 1.76, 95%CI: 1.18-2.63), LNM (OR = 1.60, 95%CI: 1.18-2.17), DM (OR = 1.90, 95%CI: 1.37-2.64) and advanced TNM stage (OR = 1.88, 95%CI: 1.36-2.60) in patients with cancers.Conclusions: High lncRNA SNHG6 expression was correlated with tumor invasion depth, LNM, DM, and advanced TNM stage, suggesting that SNHG6 may serve as a promising prognostic biomarker of human cancers.

miR-223-3p promotes cell proliferation and invasion by targeting Arid1a in gastric cancer

Accumulating evidence has indicated that microRNAs can regulate downstream signaling pathways and play an important role in various tumors. In this study, we found that miR-223-3p was differentially expressed in 40 paired gastric cancer tissues and adjacent tissues and that miR-223-3p was positively correlated with tumor invasion depth and lymph node metastasis. Luciferase reporter assay confirmed that Arid1a was the target gene of miR-223-3p. Functional assays showed that miR-223-3p promoted the proliferation and invasion of gastric cancer cells by regulating the expression of Arid1a. We also confirmed that miR-223-3p regulated the growth of gastric cancer cells in vivo, while an antagomir against miR-223-3p significantly inhibited tumor growth. In conclusion, our results demonstrated that miR-223-3p inhibits gastric cancer cell progression by decreasing the expression of Arid1a. Therefore, miR-223-3p may act as a potential therapeutic target for patients with gastric cancer.